Video

Implementing Quality Standards and Personalized Approaches into Oncology

Robert D. Orzechowski, MBA, chief operating officer, Lancaster Cancer Center, executive council member, NCODA, discusses the implementation of quality standards and personalized approaches into oncology.

Robert D. Orzechowski, MBA, chief operating officer, Lancaster Cancer Center, executive council member, NCODA, discusses the implementation of quality standards and the importance of personalized approaches in the oncology space.

It is important for every clinic to develop its own set of quality standards, and for the staff to ensure that they are applied to each individual patient and treatment. Patients might have similar diseases and malignancies, but every patient case differs to some extent, Orzechowski says. These patients cannot be grouped simply by gender because their genetic makeup is different. The most advanced treatment options are at a molecular level, Orzechowski adds, so there cannot be just one set of standards.

Medicine is the nexus of human service, science, and technology, and an organization like NCODA is an important aspect of oncology because it is a repository that embodies all of these aspects. Quality standards should not just focus on the general process of treatment; rather, they should be tailored to each patient encounter.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD